Drugs / MM-111
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01304784 | Jan 2011 → Apr 2014 | carcinoma | Merrimack Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01097460 | Apr 2010 → Jul 2013 | breast neoplasm | Merrimack Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00911898 | Jun 2009 → Mar 2012 | breast cancer, carcinoma | Merrimack Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01774851 | Jan 2013 → Jul 2015 | HER2 positive breast carcinoma, esophageal cancer, gastric cancer, gastroesophageal cancer | Merrimack Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MM-111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01774851 ↗ |
| Route | Intravenous | “drug is administered weekly via IV” NCT00911898 ↗ |